Epirubicin loading in poly(butyl cyanoacrylate) nanoparticles manifests via altered intracellular localization and cellular response in cervical carcinoma (HeLa) cells

Evangelatov, Aleksandar; Skrobanska, Ralica; Mladenov, Nikola; Petkova, Milena; Yordanov, Georgi; Pankov, Roumen

doi:10.3109/10717544.2014.962117

Cited by 15 publications

(9 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of using epirubicin silver NPs as the antitumor drug, the silver NPs could target the tumor tissues based on EPR because of the suitable size of the NPs, making the normal tissue free from the drug. Furthermore, epirubicin was wrapped onto the silver NPs in the form of a polymer and it could be slowly released to the tumor tissue, thus significantly lowering the cytotoxicity compared to free epirubicin [26,27]. This result convincingly demonstrates that the as-prepared Ag NPs are promising antitumor agents at low dosage.…”

Section: Resultsmentioning

confidence: 96%

One-Pot Synthesis of Epirubicin-Capped Silver Nanoparticles and Their Anticancer Activity against Hep G2 Cells

Ding

Chen

2019

Pharmaceutics

View full text Add to dashboard Cite

Epirubicin-capped silver nanoparticles (NPs) were synthesized through a one-pot method by using epirubicin as both the functional drug and the reducing agent of Ag+ to Ag0. The preparation process was accomplished in 1 h. In addition, the obtained epirubicin-capped silver nanoparticle was characterized by transmission electron microscopy (TEM), energy-dispersive X-ray spectroscopy (EDX), and infrared spectroscopy. The results showed that a layer of polymer epirubicin had formed around the silver nanoparticle, which was 30-40 nm in diameter. We further investigated the antitumor activity of the prepared epirubicin-capped silver nanoparticle, and the half maximal inhibitory concentration (IC50) against Hep G2 cells was 1.92 μg/mL, indicating a good antitumor property of the nanoparticle at low dosage.

show abstract

Section: Resultsmentioning

confidence: 96%

One-Pot Synthesis of Epirubicin-Capped Silver Nanoparticles and Their Anticancer Activity against Hep G2 Cells

Ding

Chen

2019

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Although CC patients in their early stages could often benefit from standard treatments of chemotherapy and radiotherapy, which significantly improve clinical outcome, the development of clinical management still remains a challenge, especially in advanced‐stage CC 2 . Epirubicin (EPI) is an initial chemotherapy drug for advanced and metastasis CC patients 3 . Over 50% of advanced CC patients eventually relapse despite their initial response to chemotherapy 4 .…”

Section: Introductionmentioning

confidence: 99%

EphA2 promotes tumorigenicity of cervical cancer by up‐regulating CDK6

Huang

Chen

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

Erythropoietin‐producing hepatocellular receptor A2 (EphA2) receptor tyrosine kinase plays an important role in tissue organization and homeostasis in normal organs. EphA2 is overexpressed in a variety of types of solid tumours with oncogenic functions. However, the role of EphA2 in cervical cancer (CC) is still needed to be further explored. Here, we examined the role of EphA2 by establishing a stable EphA2 knock‐down CC cell lines or a stable EphA2‐overexpressed CC cells lines. Overexpression of EphA2 increased cell proliferation and migration of CC while EphA2 knock‐down decreased the CC tumorigenicity. In addition, EphA2 knock‐down suppressed CC tumour development in the xenograft mouse model. Inhibition of EphA2 by AWL‐II‐41‐27, EphA2‐specific tyrosine kinase inhibitor, or knock‐down of EphA2 decreased mRNA and protein expression of cyclin‐dependent kinase (CDK) 6 in CC cells, which increased cellular susceptibility to epirubicin (EPI), an anti‐cancer chemotherapy drug. A clinicopathological study of EphA2 was conducted on a cohort of 158 human CC patients. EphA2 protein expression was positively correlated with CDK6 protein expression, invasion depth, lymph node metastasis and clinicopathological stage (P < .05). This study demonstrates the oncogenic activity of EphA2 in vitro and in vivo, which provides insights into the relevant mechanisms that might lead to novel treatments for CC.

show abstract

“…A sustained release pattern was observed in case of modified polymeric nanoparticles showing maximum drug release at pH 5.4 with 96.76% of EPI and 94.96% of PTX till 72 h. The slow release of drug was attributed to the diffusion of drugs (EPI and PTX) from the core of the nanoparticles and the breakdown of PLGA into its monomeric units of lactide and glycolic acids [ 32 ]. Also, the sustained release of the drug could be associated with the cross linking of lactic and glycolic acid moieties with the drug, resulting in the formation of a polymeric layer around the drug extending its release from the nanoparticles [ 33 ]. The results were consistent with previously reported studies in the literature.…”

Section: Resultsmentioning

confidence: 99%

Poly-(Lactic-co-Glycolic) Acid Nanoparticles for Synergistic Delivery of Epirubicin and Paclitaxel to Human Lung Cancer Cells

Sharma

Kumari

Gupta³

et al. 2020

Molecules

View full text Add to dashboard Cite

Combination therapy using chemically distinct drugs has appeared as one of the promising strategies to improve anticancer treatment efficiency. In the present investigation, poly-(lactic-co-glycolic) acid (PLGA) nanoparticles electrostatically conjugated with polyethylenimine (PEI)-based co-delivery system for epirubicin and paclitaxel (PLGA-PEI-EPI-PTX NPs) has been developed. The PLGA-PEI-EPI-PTX NPs exhibited a monodispersed size distribution with an average size of 240.93 ± 12.70 nm as measured through DLS and 70.8–145 nm using AFM. The zeta potential of 41.95 ± 0.65 mV from −17.45 ± 2.15 mV further confirmed the colloidal stability and PEI modification on PLGA nanoparticles. Encapsulation and loading efficiency along with in vitro release of drug for nanoparticles were done spectrophotometrically. The FTIR analysis of PLGA-PEI-EPI-PTX NPs revealed the involvement of amide moiety between polymer PLGA and PEI. The effect of nanoparticles on the cell migration was also corroborated through wound healing assay. The MTT assay demonstrated that PLGA-PEI-EPI-PTX NPs exhibited considerable anticancer potential as compared to the naïve drugs. Further, p53 protein expression analysed through western blot showed enhanced expression. This study suggests that combination therapy using PLGA-PEI-EPI-PTX NPs represent a potential approach and could offer clinical benefits in the future for lung cancer patients.

show abstract

Epirubicin loading in poly(butyl cyanoacrylate) nanoparticles manifests via altered intracellular localization and cellular response in cervical carcinoma (HeLa) cells

Cited by 15 publications

References 52 publications

One-Pot Synthesis of Epirubicin-Capped Silver Nanoparticles and Their Anticancer Activity against Hep G2 Cells

One-Pot Synthesis of Epirubicin-Capped Silver Nanoparticles and Their Anticancer Activity against Hep G2 Cells

EphA2 promotes tumorigenicity of cervical cancer by up‐regulating CDK6

Poly-(Lactic-co-Glycolic) Acid Nanoparticles for Synergistic Delivery of Epirubicin and Paclitaxel to Human Lung Cancer Cells

Contact Info

Product

Resources

About